(Q33952805)

English

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation (English)

1 reference

Europe PubMed Central

30 July 2017

12

object named as

Dirk Hose

1 reference

Europe PubMed Central

30 July 2017

Hartmut Goldschmidt

13

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

30 July 2017

author name string

Kai Neben

1

1 reference

Europe PubMed Central

30 July 2017

Anna Jauch

2

1 reference

Europe PubMed Central

30 July 2017

Uta Bertsch

3

1 reference

Europe PubMed Central

30 July 2017

Christiane Heiss

4

1 reference

Europe PubMed Central

30 July 2017

Thomas Hielscher

5

1 reference

Europe PubMed Central

30 July 2017

Anja Seckinger

6

1 reference

Europe PubMed Central

30 July 2017

Tina Mors

7

1 reference

Europe PubMed Central

30 July 2017

Nadine Zoe Müller

8

1 reference

Europe PubMed Central

30 July 2017

Jens Hillengass

9

1 reference

Europe PubMed Central

30 July 2017

Marc S Raab

10

1 reference

Europe PubMed Central

30 July 2017

Anthony D Ho

11

1 reference

Europe PubMed Central

30 July 2017

publication date

10 March 2010

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

95

1 reference

Europe PubMed Central

30 July 2017

7

1 reference

Europe PubMed Central

30 July 2017

1150-1157

1 reference

Europe PubMed Central

30 July 2017

Autologous hematopoietic stem-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

5 July 2018

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Clinical and biologic implications of recurrent genomic aberrations in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895040

29 October 2018

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypodiploidy is a major prognostic factor in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20220069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.016436

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33952805&oldid=1639605659"